Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics		$15.19	$8.13 ▼ $26.28	$24.33M	0.41	24,701 shs	237,144 shs
MGNX MacroGenics	$1.37 -2.1%	$1.43	$0.99 ▼ $5.77	$86.50M	2.2	777,477 shs	526,605 shs
OCX OncoCyte	$3.23 -0.9%	$3.00	$1.92 ▼ $4.75	$92.38M	0.95	57,873 shs	14,324 shs
OPTN OptiNose	$9.60	$9.32	$4.82 ▼ $20.03	$97.22M	-0.88	63,485 shs	N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	0.00%	0.00%	0.00%	+14.90%	-31.73%
MGNX MacroGenics	0.00%	-9.21%	-21.66%	-39.87%	-66.48%
OCX OncoCyte	0.00%	-4.15%	+6.60%	+16.19%	+17.88%
OPTN OptiNose	0.00%	0.00%	+2.13%	+82.16%	-40.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	1.2799 of 5 stars	3.0	0.0	4.2	0.0	0.8	0.0
MGNX MacroGenics	3.8559 of 5 stars	3.2	1.0	4.4	2.8	2.5	0.6
OCX OncoCyte	2.7088 of 5 stars	3.4	4.0	0.0	3.3	0.8	0.6
OPTN OptiNose	3.2466 of 5 stars	1.0	5.0	4.2	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	2.00	Hold	$36.00	∞ Upside
MGNX MacroGenics	2.40	Hold	$5.71	316.80% Upside
OCX OncoCyte	2.75	Moderate Buy	$6.06	87.69% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside

Current Analyst Ratings Breakdown

Latest CARA, OPTN, OCX, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/13/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
4/8/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
3/28/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00
3/25/2025	OCX OncoCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$4.00 ➝ $4.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
MGNX MacroGenics	$152.43M	0.57	N/A	N/A	$2.46 per share	0.56
OCX OncoCyte	$3.84M	24.04	N/A	N/A	$2.48 per share	1.30
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
MGNX MacroGenics	-$9.06M	-$0.89	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	8/5/2025 (Estimated)
OCX OncoCyte	-$27.78M	-$3.53	N/A	N/A	N/A	-6,122.29%	-269.32%	-59.71%	8/14/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)

Latest CARA, OPTN, OCX, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
5/12/2025	Q1 2025	OCX OncoCyte	-$0.24	-$0.26	-$0.02	-$0.26	$0.13 million	$2.14 million
3/26/2025	Q4 2024	OPTN OptiNose	-$0.70	-$0.03	+$0.67	-$0.03	$21.02 million	$21.47 million
3/24/2025	Q4 2024	OCX OncoCyte	-$0.40	$0.48	+$0.88	-$1.93	$0.16 million	$1.49 million
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.77	4.71
MGNX MacroGenics	N/A	3.75	3.69
OCX OncoCyte	N/A	0.53	0.50
OPTN OptiNose	N/A	0.79	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%
MGNX MacroGenics	96.89%
OCX OncoCyte	55.35%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	3.10%
MGNX MacroGenics	13.00%
OCX OncoCyte	2.05%
OPTN OptiNose	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable
OCX OncoCyte	120	28.60 million	17.18 million	No Data
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable

CARA, OPTN, OCX, and MGNX Headlines

Recent News About These Companies

HC Wainwright Estimates OptiNose's Q2 Earnings (NASDAQ:OPTN)

May 23, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by D. E. Shaw & Co. Inc.

May 23, 2025 | marketbeat.com

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21, 2025 | finance.yahoo.com

HC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)

May 21, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) is Stonepine Capital Management LLC's 8th Largest Position

May 20, 2025 | marketbeat.com

Optinose Stockholders Approve Merger with Paratek

May 16, 2025 | tipranks.com

Bridgeway Capital Management LLC Sells 227,387 Shares of OptiNose, Inc. (NASDAQ:OPTN)

May 16, 2025 | marketbeat.com

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Renaissance Technologies LLC

May 10, 2025 | marketbeat.com

OptiNose (OPTN) to Release Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

Bleichroeder LP Trims Position in OptiNose, Inc. (NASDAQ:OPTN)

May 7, 2025 | marketbeat.com

Geode Capital Management LLC Has $576,000 Stake in OptiNose, Inc. (NASDAQ:OPTN)

May 5, 2025 | marketbeat.com

Acorn Capital Advisors LLC Makes New $2.82 Million Investment in OptiNose, Inc. (NASDAQ:OPTN)

May 4, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by MVM Partners LLC

May 3, 2025 | marketbeat.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

April 29, 2025 | businesswire.com

Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income

March 28, 2025 | msn.com

Optinose reports Q4 EPS (3c) vs ($1.33) last year

March 27, 2025 | markets.businessinsider.com

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

March 26, 2025 | markets.businessinsider.com

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

March 26, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

March 25, 2025 | morningstar.com

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

March 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?
By Chris Markoch | May 14, 2025
View U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?

CARA, OPTN, OCX, and MGNX Company Descriptions

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

MacroGenics NASDAQ:MGNX

$1.37 -0.03 (-2.07%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.36 -0.01 (-0.80%)

As of 04:00 AM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

OncoCyte NASDAQ:OCX

$3.23 -0.03 (-0.92%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.32 +0.09 (+2.79%)

As of 04:00 AM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time